FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Lucia Campos CarrascosaAdriaan A van BeekValeska de RuiterMichail DoukasJie WeiTimothy S FisherKeith ChingWenjing YangKarlijn van LoonPatrick P C BoorYannick S RakkéLisanne NoordamPascal DoorneboschDirk GrünhagenKees VerhoefWojciech G PolakJan N M IJzermansIrene NiYik Andy YeungShahram Salek-ArdakaniDave SprengersJaap KwekkeboomPublished in: Journal for immunotherapy of cancer (2021)
OX40 is overexpressed on CD4+ TILs and thus represents a promising target for immunotherapy. Targeting OX40 with currently used agonistic antibodies may be inefficient due to lack of OX40 multimerization. Thus, Fc engineering is a powerful tool in enhancing the agonistic activity of αOX40 antibody and may shape the future design of antibody-mediated αOX40 immunotherapy.